IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of	: Meade, C. J. M. et al) Art Unit:	1614	-	
U.S. Appln. No.	-) Examiner:	Phyllis G. Spivak		
Confirmation No.	: 7889		*		
U.S. Filing Date					
	: New Pharmaceutical Compos	itions based on N	_	\bigcap	
Attny. Docket No.	NK1 Receptor Antagonists: 1/1363		fel not	ned	
Commissioner for	Patents		٨).		
P. O. Box 1450	*				
Alexandria, VA 22	2313-1450			. 03	
November 1, 2004	*		4 1		
TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STÄTEMENT					
Sir:			•	•	
Transmitted herew	ith concerning the subject appli	cation is an Infor	mation Disclosure		
	449A/B) under 37 C.F.R. §§1.5				
	cations, cited therein and as mor				
	-				
1.97(b).	This Statement is being file	de i) within three	(3) months of the filing		
	application other than a continue	•	•		
	n three (3) months of the date of				
37 C.F.R. §1.491 i	n an international application; ii	i) before the mai	ling of a first Office action	. *	
	before the mailing of a first O	ffice action after	the filing of a request for		
continued examina	ation under 37 C.F.R. §1.114.				
	This Statement is being file				
	ut before the mailing date of: i)				
	e under 37 C.F.R. §1.311, or iii)		herwise closes prosecution		
in the application.	This Statement is being accomp	banied by:			
☐ As	statement as specified in 37 C.F.	R. §1.97(e) [see	below]; or		
				•	
∑ The	fee set forth in 37 C.F.R. §1.17	(n)		23.5	
	, 100 501 10141 11 5 7 0.11 120 31.11	(P)-		10614362	
			3		
\boxtimes	The Commissioner is hereby			022955	
\$18	0.00 fee set forth in 37 C.F.R. §	1.17(p) to Depos	it Account No.	65.0 0	

1 of 3

11/22/2004 CBETANCO 00000002 022955 10614362

	ent as s	This Statement is being filed after the period specified in 37 C.F.R. on or before payment of the issue fee. This Statement is accompanied by a specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e	
	counte	Each item of information contained in the instant information disclosure ent was first cited in any communication from a foreign patent office in a repart foreign application not more than three (3) months prior to the filing of tant information disclosure statement; or
	foreign making inform §1.56(No item of information contained in the instant information disclosure ent was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing this certification after g reasonable inquiry, no item of information contained in the instant sation disclosure statement was known to any individual designated in 37 C.F.R. c) more than three (3) months prior to the filing of the instant information sure statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
counte in secti	part ap on 1.56	d). Each item of information contained in the accompanying information ement was cited in a communication from a foreign patent office in a plication, which communication was not received by any individual designated (c) more than thirty (30) days prior to the filing of the accompanying sclosure statement.
	quired u	ommissioner is hereby authorized to charge payment of any additional filing under 37 C.F.R. §1.16 and any patent application processing fees under 37 or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Patent Department

Ridgefield, CT 06877

Tel: (203) 798-4310

Date: November 1, 2004

Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Respectfully submitted,

Timothy X. Witkowski Attorney for Applicant(s)

Reg. No. 40,232

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents

P. O. Box 1450

Alexandria, VA 22313-1450

on November 1, 2004

Timothy X. Witkowski, Reg. No. 40,232